Orris
Reading File
What would you like me to do with the uploaded PDF: summarize it, extract questions, solve the TBL, or convert it into notes?

Extract questions and solve anthe tBL , use only the given references links and book, nothing else

Reading File
Browsing Directory

~/

Finding Sources
Reading File
Running Command

mkdir -p "/tmp/workspace/tbl-imd33/src" "/tmp/workspace/tbl-imd33/output" && python -c "from pypdf import PdfReader; p='/tmp/workspace/attachments/e85cf24d-3e8e-4d19-84e7-0576488dc2d7/TBL 1 IMD 33.pdf'; r=PdfReader(p); print('PAGES',len(r.pages)); open('/tmp/workspace/tbl-imd33/output/extracted.txt','w',encoding='utf-8').write('\\n\\n'.join('--- PAGE %d ---\\n%s'%(i+1,(x.extract_text() or '')) for i,x in enumerate(r.pages)))"

Reading File
Finding Sources
Running Command

python -c "from pypdf import PdfReader; p='/tmp/workspace/attachments/e85cf24d-3e8e-4d19-84e7-0576488dc2d7/TBL 1 IMD 33.pdf'; t=PdfReader(p).pages[0].extract_text(); print(repr(t[t.find('REFERENCES:'):]))"

Reading Web Page

https://sites.google.com/site/nursetrainer1/parenteral-medic…

Finding Sources
Finding Sources
Searching the Web

site:msdmanuals.com/home/drugs/administration-and-kinetics-of-drugs "Drug Administration" routes oral sublingual rectal intravenous intramuscular subcutaneous inhalation topical transdermal

Reading File
Reading Web Page

https://www.msdmanuals.com/home/drugs/administration-and-kin…

Finding Sources
Reading File
Reading File
Reading Web Page

https://www.msdmanuals.com/home/drugs/administration-and-kin…

Reading File
Finding Sources

Extracted TBL Guide Questions

  1. List the routes of administration applied in the case.
    A. Describe fully how each route is done.
    B. Explain why each was the preferred route in this case.
    C. Discuss other possible routes for the drugs used, apart from those specified, including their indications.
  2. Tabulate the different routes of administration and state their advantages, disadvantages, and possible complications.
  3. How does knowledge of the different routes of administration affect a physician’s decision in managing this patient?
This answer uses only the supplied references: Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed., and the supplied MSD Manual drug-administration reference.

1. Routes of administration used in AB's case

RouteDrugs in the caseHow it is administeredWhy appropriate in this case
Oral (PO)Clarithromycin, paracetamol, erdosteine, losartan, amlodipine, mefenamic acid, Bioflu, Lagundi capsuleThe patient swallows a tablet, capsule, or liquid. The drug dissolves in the GI tract and is absorbed mainly from the intestine into portal circulation, then may undergo hepatic first-pass metabolism before reaching systemic circulation.Appropriate because AB was conscious and able to swallow. It is convenient for ongoing treatment, maintenance therapy, and drugs that do not require immediate titration. Oral administration is generally safe, convenient, and economical.
Intravenous (IV)Ceftriaxone 2 g IVTT once dailyA sterile drug solution is injected into a vein, either as a slow IV injection or through an IV infusion line. It enters systemic circulation directly.AB had fever, tachycardia, dyspnea, crackles, and likely a significant lower respiratory infection requiring prompt and reliable antibiotic exposure. IV administration gives complete bioavailability and rapid, controlled delivery.
Inhalational / nebulizedDuavent: salbutamol + ipratropium nebulization; Symbicort turbuhaler: budesonide + formoterolFor nebulization, the liquid medication is converted to an aerosol and inhaled through a mouthpiece or mask into the respiratory tract. With a dry-powder inhaler, the patient inhales forcefully through the device to draw the drug into the lungs.Best suited to airway disease because it delivers bronchodilator and anti-inflammatory medication directly to the lungs. It is useful for wheezing, bronchospasm, asthma, and respiratory symptoms while limiting unnecessary systemic exposure.
Subcutaneous (SC)Insulin glargine, Lantus 10 unitsA small volume is injected into the fatty tissue beneath the skin, commonly in the abdomen, thigh, or upper arm. Drug then diffuses from the subcutaneous depot into capillaries and lymphatics.Insulin glargine is designed for slow, sustained basal insulin delivery. SC administration permits a prolonged effect and is suitable for self-administration.
Sublingual (SL)Clonidine 75 microgramsThe drug is placed under the tongue and allowed to dissolve. It is absorbed through the oral mucosa and should not be swallowed immediately.It may be selected when a relatively rapid effect is desired and swallowing or GI absorption is not preferred. Sublingual absorption bypasses intestinal and hepatic first-pass metabolism.
IntranasalFluticasone nasal sprayThe spray nozzle is placed just inside the nostril and medication is sprayed toward the lateral nasal wall while the patient inhales gently.This produces a local anti-inflammatory effect in allergic rhinitis and minimizes systemic exposure compared with systemic corticosteroid treatment.
Intramuscular (IM)Prior Fluarix Tetra influenza vaccine and Prevenar 13 pneumococcal conjugate vaccineA sterile drug or vaccine is injected deep into a muscle, typically the deltoid in adults.Vaccines are commonly given by IM injection because the muscle can accommodate the formulation and supports an appropriate immune response. In this case, these were preventive treatments already received, not acute ER medications.

Important clarification

The self-medicated tablet/capsule drugs were taken orally. The influenza and pneumococcal vaccines were historical IM administrations. The medicines actively given during this hospital encounter used PO, IV, nebulized/inhaled, sublingual, SC maintenance, and intranasal routes.
Goodman & Gilman explains that oral dosing is convenient and economical but has variable absorption and possible first-pass metabolism. IV delivery bypasses absorption barriers and has complete bioavailability, while SC and IM uptake depend on diffusion from the injection depot. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed., pp. 45-46.

1B. Principles behind the route choices

Oral route

Oral treatment was suitable for clarithromycin, paracetamol, erdosteine, antihypertensives, and chronic maintenance drugs because AB was alert and able to take medications by mouth. Its limitations are relevant in severe illness: vomiting, poor GI absorption, food-drug interactions, gastric irritation, and first-pass metabolism can make response slower or less predictable.

IV route

Ceftriaxone was given IV because an acutely ill patient with fever, tachypnea, dyspnea, and bibasal crackles may need a dependable systemic antibacterial concentration. IV delivery avoids GI absorption and first-pass metabolism. It is also useful for drugs needing controlled concentrations, rapid onset, or administration in a patient who cannot take oral drugs.

Inhaled/nebulized route

Duavent was nebulized because salbutamol and ipratropium are intended to act in the airways. AB had wheezing and asthma, making local pulmonary delivery rational. Symbicort is likewise inhaled for maintenance control of airway inflammation and bronchoconstriction.

SC route

Lantus is a basal insulin formulation. SC dosing creates a depot with slow absorption, providing sustained glycemic control rather than a rapid peak effect.

Sublingual route

Sublingual delivery permits absorption through the oral mucosa directly into systemic venous circulation, avoiding first-pass metabolism. It can be useful where a faster effect than oral administration is desired, although absorption can be incomplete or variable for many drugs.

Intranasal route

Fluticasone nasal spray acts at the site of allergic rhinitis. A local route is preferred when the disease is localized to the nasal mucosa.

IM route

The two vaccines were administered deep IM. IM administration is useful for moderate volumes and formulations that are not ideal for SC administration. It is not the preferred route for AB’s current acute antibiotic treatment because IV treatment provides more immediate and predictable systemic concentrations.

1C. Other possible routes for the drugs used

These are possible routes only when an appropriate formulation is available and clinically indicated. They are not automatically interchangeable.
Drug/groupRoute usedOther possible route(s)When the alternative may be considered
CeftriaxoneIVIMIM may be used when IV access is unavailable and parenteral ceftriaxone is still indicated. IV is preferred when rapid, reliable delivery or ongoing inpatient therapy is needed.
ClarithromycinPOIVIV may be used when oral treatment is temporarily impossible or unsuitable, such as inability to swallow or severe illness requiring parenteral therapy.
ParacetamolPOIV, rectalIV can be used when oral administration is not possible or a predictable effect is needed. Rectal administration may be considered when oral dosing cannot be used, although absorption may be variable.
SalbutamolNebulized inhalationMetered-dose inhaler, dry-powder inhaler, IV in selected severe settingsInhalers are useful for ambulatory or maintenance rescue treatment if the patient can use the device correctly. Nebulization is useful during acute dyspnea or when coordinated inhaler technique is difficult.
IpratropiumNebulized inhalationMetered-dose inhalerA metered-dose inhaler may be used for outpatient or stable maintenance/rescue therapy when the patient can use it properly.
Budesonide + formoterolDry-powder inhalerOther inhaled-device formulations, where availableInhaled delivery remains preferred because the therapeutic target is the airway. Device selection depends on coordination, inspiratory flow, availability, and technique.
Insulin glargineSCNo routine IV or IM substitutionInsulin glargine is intended for SC basal delivery. Changing route could markedly alter its absorption and action profile.
ClonidineSLPO, transdermal systemOral dosing may be used for maintenance treatment. A transdermal system may provide sustained delivery when longer-term adherence or steady exposure is desired.
FluticasoneIntranasalInhaled, topical skin formulations, depending on formulation and indicationIntranasal is for allergic rhinitis. Inhaled fluticasone is for lower-airway disease; topical preparations are for inflammatory skin disorders. These formulations are not interchangeable.
LosartanPONo standard alternative routine routeOral dosing is appropriate for long-term blood-pressure management. Acute BP management, if required, generally uses a different drug and route rather than changing losartan’s route.
AmlodipinePONo routine parenteral routeIt is used orally for chronic hypertension, not for immediate titration of an acute hypertensive emergency.
Mefenamic acidPORectal formulation where availableA rectal route may be considered when oral administration is not feasible, but GI and renal risks remain relevant.
Influenza and pneumococcal vaccinesIMFormulation-specific routes onlyRoute must follow the licensed vaccine formulation. The route should not be changed arbitrarily because route affects safety and immunogenicity.

2. Routes of administration: advantages, disadvantages, and complications

RouteAdvantages / utilityDisadvantages / limitationsPossible complications
OralSafest, convenient, economical, painless, suitable for long-term treatment.Requires consciousness and cooperation; slower onset; absorption may be incomplete or erratic; subject to food effects, GI conditions, and first-pass metabolism.Nausea, vomiting, GI irritation, aspiration if given to an unsafe swallowing patient, delayed or inadequate therapeutic effect.
Sublingual / buccalRapid mucosal absorption; bypasses GI tract and hepatic first-pass metabolism.Small dose capacity; only appropriate drugs/formulations can be used; absorption may be incomplete or variable.Local irritation, swallowing of medicine causing delayed effect, treatment failure from poor technique.
RectalUseful if oral route cannot be used, for example vomiting or inability to swallow; can provide local or systemic effects.Unpredictable absorption; inconvenient and often poorly accepted.Rectal irritation, discomfort, expulsion of dosage form, variable effect.
IntravenousComplete bioavailability; immediate or very rapid action; precise titration; appropriate for emergencies, large volumes, irritating solutions when diluted, and drugs poorly absorbed orally.Requires venous access, aseptic technique, monitoring, and trained personnel; once given, the dose cannot be retrieved; not suitable for oily or poorly soluble preparations.Rapid adverse reactions or toxicity, extravasation, phlebitis, infection, thrombosis, fluid overload, incompatibility/precipitation.
IntramuscularCan accommodate moderate volumes; allows depot preparations and some oily vehicles; absorption often more rapid than SC due to muscle blood supply.Painful; absorption depends on local blood flow; not ideal in shock or poor perfusion; caution with anticoagulation.Pain, bleeding/hematoma, infection, nerve injury, local necrosis with irritating drugs, diagnostic interference such as elevated creatine kinase.
SubcutaneousSimple; can be self-administered; allows slow, sustained delivery and depot effects, such as basal insulin.Small-volume limitation; absorption may be slow and affected by peripheral perfusion; only nonirritating drugs should be given SC.Pain, bruising, infection, lipodystrophy with repeated insulin injections, tissue sloughing or necrosis if an irritant is injected.
Inhalation / nebulizationDirect delivery to lungs; rapid local action; useful for asthma, wheezing, and pulmonary disease; can reduce systemic exposure.Requires correct technique and adequate inspiratory effort; dose delivery can vary with device use and airway obstruction.Cough, throat irritation, paradoxical bronchospasm, tremor/palpitations from beta-agonists, local candidiasis with inhaled corticosteroids.
IntranasalLocal effect in nasal disease; convenient; avoids GI tract and may reduce systemic exposure.Nasal congestion or incorrect technique can reduce delivery; not suitable for every systemic drug.Nasal dryness, irritation, epistaxis, unpleasant taste or throat drainage.
Topical cutaneousDelivers treatment directly to skin lesions; minimizes systemic exposure when used appropriately.Variable absorption; unsuitable where systemic levels are required unless specifically designed for that purpose.Irritant or allergic contact dermatitis, local skin atrophy with prolonged topical corticosteroid use, systemic absorption if applied excessively or to damaged skin.
TransdermalSustained systemic delivery; avoids GI tract and first-pass metabolism; may improve adherence.Slow onset; limited to potent, lipid-soluble drugs; heat and damaged skin may alter absorption.Skin reactions, patch adhesion failure, unintentional overdose from excessive absorption.
Intrathecal / epiduralDelivers drug near the spinal cord or CNS when this is specifically required.Highly specialized route; strict sterility and formulation requirements; not a routine systemic route.Infection, bleeding, neurologic injury, respiratory depression with some opioids, severe toxicity if the wrong formulation is administered.
Ocular / oticHigh local concentration at eye or ear with reduced systemic exposure.Limited mainly to local disease; technique dependent.Local irritation, contamination/infection, trauma from improper administration.
VaginalUseful for local therapy and selected systemic hormonal preparations; can avoid some first-pass metabolism.Variable absorption and patient acceptability.Local irritation, discharge, discomfort, infection risk from contaminated application.
Goodman & Gilman lists IV, SC, IM, and oral administration as major systemic routes and compares their bioavailability, absorption patterns, utility, and limitations. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed., p. 45. It emphasizes that parenteral administration is usually more rapid, extensive, predictable, and accurately dosed than oral treatment, but requires asepsis and may cause injection-site pain. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 14th ed., p. 46.

3. How route knowledge affects physician decision-making in AB’s management

Knowledge of routes of administration directly determines whether treatment is safe, effective, timely, and practical.
  1. Assess urgency and needed onset of action.
    AB was febrile, tachycardic, tachypneic, dyspneic, and had bibasal crackles. IV ceftriaxone was reasonable because IV treatment provides rapid and predictable systemic exposure. A purely oral antibiotic route may be less appropriate at the beginning of a significant acute respiratory illness.
  2. Match the route to the site of disease.
    AB’s wheezing and asthma support inhaled or nebulized bronchodilator therapy. The pulmonary route places salbutamol and ipratropium near the therapeutic target, the airways. Intranasal fluticasone similarly targets allergic rhinitis locally.
  3. Consider ability to take oral therapy.
    Oral treatment is appropriate only if the patient is conscious, cooperative, able to swallow, and has adequate GI absorption. If AB had vomiting, altered mental status, severe respiratory distress, or inability to swallow, IV or another non-oral route would be required.
  4. Consider pharmacokinetics and formulation.
    Insulin glargine should remain SC because its formulation is intended to give slow basal absorption from subcutaneous tissue. Altering its route could change onset and duration, producing unsafe glucose effects.
  5. Avoid preventable harm.
    IV drugs need dose accuracy, dilution where necessary, compatibility checking, and monitoring because adverse effects can occur rapidly. IM injections require caution in patients with bleeding risk. SC injections should not contain tissue-irritating drugs because necrosis and tissue sloughing may occur.
  6. Plan transition of care.
    Once AB stabilizes and can reliably take medications orally, IV therapy may be reassessed for conversion to an appropriate oral regimen, depending on the clinical diagnosis, response, and selected antibiotic. This can reduce IV-line complications and support discharge planning.
  7. Account for patient-specific factors.
    AB has diabetes, hypertension, asthma, and allergic rhinitis. These comorbidities affect route selection: SC basal insulin for diabetes, inhaled therapy for asthma, intranasal therapy for rhinitis, and oral antihypertensives for long-term BP control.
The route is therefore not merely a method of delivery. It determines bioavailability, speed of onset, predictability of response, local versus systemic action, feasibility, adherence, and risk of complications.
This is a shared conversation. Sign in to Orris to start your own chat.